过氧化物酶体增殖物激活受体3在喉鳞状细胞癌中的差异表达。
Differential expression of peroxiredoxin 3 in laryngeal squamous cell carcinoma.
作者信息
Zhang Hua, Liu Xuexia, Chen Lei, Cai Li, Li Ning, Zhu Peng, Chen Jian, Song Xicheng, Li Guojun
机构信息
Department of Otolaryngology-Head and Neck Surgery, Yuhuangding Hospital of Qingdao University, Yantai, China.
Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Oncotarget. 2017 Jan 10;8(2):3471-3480. doi: 10.18632/oncotarget.13838.
Peroxiredoxin (PRDX) proteins are involved in carcinogenesis. PRDX3, which is predominantly localized in mitochondria and up-regulated in several human cancers, seems to confer increased treatment resistance and aggressive phenotypes. This study examined the expression profile of PRDX3 and its possible clinical value in laryngeal squamous cell carcinoma (LSCC). The expression of PRDX3 in LSCC samples was confirmed by Western blotting and further analyzed by immunohistochemistry in LSCC samples of different clinical pathological stages. The results showed that up-regulated expression of PRDX3 was observed in LSCC and associated with poor differentiation (P < 0.01), primary tumor location, N category and tumor stage (P < 0.05). Knockdown of PRDX3 in the Hep-2 laryngeal carcinoma epithelial cell line significantly enhanced Hep-2 cells' apoptosis and inhibited their proliferation and migration. Taken together, our results suggest that PRDX3 has substantial clinical impact on the progression of LSCC and shed new light on the role of PRDX3 in treatment resistance and aggressive phenotypes in LSCC.
过氧化物酶（PRDX）蛋白参与肿瘤发生。PRDX3主要定位于线粒体，在多种人类癌症中上调，似乎赋予了更高的治疗抗性和侵袭性表型。本研究检测了PRDX3在喉鳞状细胞癌（LSCC）中的表达谱及其可能的临床价值。通过蛋白质免疫印迹法证实了PRDX3在LSCC样本中的表达，并在不同临床病理分期的LSCC样本中通过免疫组织化学进一步分析。结果显示，LSCC中观察到PRDX3表达上调，且与低分化（P < 0.01）、原发肿瘤位置、N分期和肿瘤分期相关（P < 0.05）。在Hep-2喉癌细胞系中敲低PRDX3可显著增强Hep-2细胞的凋亡，并抑制其增殖和迁移。综上所述，我们的结果表明PRDX3对LSCC的进展具有重大临床影响，并为PRDX3在LSCC治疗抗性和侵袭性表型中的作用提供了新的线索。
Zotero 插件